{"ticker": {"uuid": "e3cdb4a9-b940-4cea-8d7c-0f662e2ac923", "symbol": "ORIC", "name": "Oric Pharmaceuticals\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "How ORIC\u2019s Global Phase 3 Rinzimetostat Trial with Bayer\u2019s NUBEQA Has Changed Its Investment Story (ORIC)", "summary": "ORIC Pharmaceuticals has launched the Himalayas-1 global Phase 3 trial for rinzimetostat with Bayer's NUBEQA in metastatic castration-resistant prostate cancer, enrolling about 600 patients. This trial positions rinzimetostat as a late-stage asset and a major clinical catalyst fo", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/how-orics-global-phase-3-rinzimetostat-trial-with-bayers-nub/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-15T11:43:51", "published_display": "15 Jul 2026 11:43", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC Pharmaceuticals initiates phase 3 prostate cancer trial", "summary": "ORIC Pharmaceuticals (NASDAQ:ORIC) has initiated its Himalayas-1 global Phase 3 trial for metastatic castration-resistant prostate cancer, enrolling approximately 600 patients across 25 countries. The trial will evaluate rinzimetostat in combination with darolutamide, with primar", "url": "https://m.uk.investing.com/news/stock-market-news/oric-pharmaceuticals-initiates-phase-3-prostate-cancer-trial-93CH-4770442?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-15T02:42:00", "published_display": "15 Jul 2026 02:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/oric-pharmaceuticals-starts-phase-3-210723202.html", "source_name": "MT Newswires", "published_at": "2026-07-14T21:07:23+00:00", "published_display": "14 Jul 2026 21:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC\u00ae Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA\u00ae (Darolutamide), Supported by Clinical Collaboration with Bayer", "summary": "ORIC Pharmaceuticals has initiated the Himalayas-1 global Phase 3 registrational trial for metastatic castration-resistant prostate cancer (mCRPC), evaluating rinzimetostat in combination with Bayer's NUBEQA\u00ae (darolutamide). This trial, supported by a collaboration with Bayer pro", "url": "https://www.manilatimes.net/2026/07/15/tmt-newswire/globenewswire/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with-bayer/2384536", "source_name": "The Manila Times", "published_at": "2026-07-14T20:26:57", "published_display": "14 Jul 2026 20:26", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bayer Will Provide NUBEQA at No Cost for ORIC\u2019s Global Trial", "summary": "ORIC Pharmaceuticals announced the initiation of its global Phase 3 Himalayas-1 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC), in collaboration with Bayer. Bayer will supply NUBEQA (darolutamide) free of charge for the trial, which will enroll", "url": "https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-awcsgl0auq0k.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:04:57", "published_display": "14 Jul 2026 20:04", "sentiment": "positive", "sentiment_pct": 70, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Discipline and Rules-Based Execution in ORIC Response", "summary": "Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is exhibiting mixed sentiment with a mid-channel oscillation pattern. AI models have generated three distinct trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014tailored to different risk profiles. The analysis highlights an ", "url": "https://news.stocktradersdaily.com/news_release/91/Discipline_and_Rules-Based_Execution_in_ORIC_Response_070926055001_1783590601.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-09T05:41:49", "published_display": "09 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oric Pharmaceuticals director Heyman sells $3,600 in stock", "summary": "Richard A. Heyman, a director at Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), sold 300 shares of company stock for $3,600. The transaction was executed on July 6, 2026, under a Rule 10b5-1 trading plan. This sale comes amidst significant analyst upgrades and promising clinical data ", "url": "https://www.investing.com/news/insider-trading-news/oric-pharmaceuticals-director-heyman-sells-3600-in-stock-93CH-4782496", "source_name": "Investing.com", "published_at": "2026-07-08T23:11:07", "published_display": "08 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Oric Pharmaceuticals Inc For: 8 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Oric Pharmaceuticals Inc. on July 8th. The brief piece indicates that ORIC experienced a slight increase of 0.32%. The content primarily presents market data and related news.", "url": "https://ng.investing.com/news/stock-market-news/form-4-oric-pharmaceuticalsinc-for-8-july-93CH-2591808", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T21:41:49", "published_display": "08 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oric Pharmaceuticals (ORIC) entity sells 300 shares under 10b5-1 plan", "summary": "An entity linked to Oric Pharmaceuticals director Richard A. Heyman, RAHD Capital, LLC, sold 300 shares of ORIC common stock at $12.00 per share on July 6, 2", "url": "https://www.stocktitan.net/sec-filings/ORIC/form-4-oric-pharmaceuticals-inc-insider-trading-activity-0373dc5a5db7.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:11:07", "published_display": "08 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Oric Pharmaceuticals, Inc. \u2013 NASDAQ:ORIC", "summary": "This article provides a financial overview for Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) on TradingView. It specifically highlights the company's forward price-to-sales ratio. The content also lists various features and financial data points available through the TradingView plat", "url": "https://www.tradingview.com/symbols/NASDAQ-ORIC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T19:09:28", "published_display": "07 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC focuses on oncology pipeline as Oric Pharmaceuticals positions for long-term growth", "summary": "Oric Pharmaceuticals (ORIC) is a clinical-stage biotechnology company concentrating on small-molecule therapies to overcome resistance mechanisms in cancer treatment, a significant challenge in oncology. The company's strategy involves translating preclinical insights into clinic", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/oric-focuses-on-oncology-pipeline-as-oric-pharmaceuticals-positions-for/69715694", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:40:48", "published_display": "07 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Oric Pharmaceuticals, Inc. \u2013 DUS:4TZ", "summary": "This article provides financial information for Oric Pharmaceuticals, Inc. (DUS:4TZ), specifically focusing on its forward price-to-sales ratio. The content is sourced from TradingView and includes data from ICE Data Services and FactSet, indicating a focus on financial metrics f", "url": "https://www.tradingview.com/symbols/DUS-4TZ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T10:40:48", "published_display": "07 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan", "summary": "Oric Pharmaceuticals (NASDAQ: ORIC) filed a Form 144 indicating a proposed sale of 7,000 Common shares through J.P. Morgan Securities LLC. The filing details two stock option exercises, each for 3,500 shares, dated August 25, 2016, and July 6, 2026. This notification provides tra", "url": "https://www.stocktitan.net/sec-filings/ORIC/144-oric-pharmaceuticals-inc-sec-filing-0e54b280e9c2.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:12:06", "published_display": "06 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Oric Pharmaceuticals, Inc. SEC Filing", "summary": "Oric Pharmaceuticals, Inc. (ORIC) filed a Form 144 with the SEC, indicating a proposed sale of 6,400 common shares by a filer who acquired them via stock option exercise on July 31, 2015. The shares, valued at $76,800, are expected to be sold on July 6, 2026, through J.P. Morgan ", "url": "https://www.stocktitan.net/sec-filings/ORIC/144-oric-pharmaceuticals-inc-sec-filing-0ed3d636d605.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:12:06", "published_display": "06 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Oric Pharmaceuticals, Inc. \u2013 NASDAQ:ORIC", "summary": "This page from TradingView provides financial information specifically focusing on the \"Price to earnings forward\" metric for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC). It indicates the company's ticker symbol, NASDAQ listing, and highlights specific financial data points related ", "url": "https://www.tradingview.com/symbols/NASDAQ-ORIC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:11:00", "published_display": "04 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "ORIC Pharmaceuticals announced inducement grants to three new non-executive employees, consisting of 44,400 non-qualified stock options and 7,200 restricted stock units. These grants were approved by ORIC's Compensation Committee and serve as a material inducement to employment i", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321570/0/en/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-03T05:39:58", "published_display": "03 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC awards new hires 44,400 stock options and 7,200 RSUs", "summary": "ORIC Pharmaceuticals (Nasdaq: ORIC) announced inducement equity grants to three new non-executive employees who started in June 2026. The grants, made on July 1, 2026, include 44,400 non-qualified stock options and 7,200 restricted stock units, approved under Nasdaq Rule 5635(c)(", "url": "https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-64rrrbs3lx9a.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:29", "published_display": "02 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Are Bullish on Top Healthcare Picks", "summary": "Wall Street analysts are showing bullish sentiment towards several healthcare companies, including Monopar Therapeutics Inc (MNPR), Oric Pharmaceuticals (ORIC), and Tango Therapeutics (TNGX). Analysts from Piper Sandler, Barclays, H.C. Wainwright, and Canaccord Genuity have issue", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3050918/wall-street-analysts-are-bullish-on-top-healthcare-picks/", "source_name": "The Globe and Mail", "published_at": "2026-07-01T04:40:30", "published_display": "01 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation", "summary": "Wedbush has reiterated its \"outperform\" recommendation for ORIC Pharmaceuticals (ORIC). The article is brief and does not provide further details on the rationale behind this rating.", "url": "https://www.msn.com/en-us/money/markets/wedbush-reiterates-oric-pharmaceuticals-oric-outperform-recommendation/ar-AA1RYzxw?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-30T04:40:30", "published_display": "30 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. \u2013 NASDAQ:ORIC", "summary": "The article provides a financial overview of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), focusing on its enterprise value to EBITDA forward metric. It details the company's financial data on the TradingView platform, including market performance and other financial indicators. The", "url": "https://www.tradingview.com/symbols/NASDAQ-ORIC/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T08:14:17", "published_display": "29 Jun 2026 08:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Oric Pharmaceuticals, Inc. \u2013 FWB:4TZ", "summary": "This article provides the \"Price to book forward\" value for Oric Pharmaceuticals, Inc. (FWB:4TZ) on the Frankfurt Stock Exchange. It indicates that the market is currently closed with no trades. The article also lists various financial and community features available on the Trad", "url": "https://www.tradingview.com/symbols/FWB-4TZ/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:09:46", "published_display": "29 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Oric Pharmaceuticals, Inc. \u2013 NASDAQ:ORIC", "summary": "This article focuses on the enterprise value to EBIT forward for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC). It appears to be a financial data point presented on TradingView, indicating a specific financial metric for the company. The content primarily consists of navigation and bo", "url": "https://www.tradingview.com/symbols/NASDAQ-ORIC/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:09:46", "published_display": "28 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of ORIC and Institutional Flows", "summary": "This article analyzes Oric Pharmaceuticals Inc. (NASDAQ: ORIC), identifying strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with specific entry, target, and stop-loss l", "url": "https://news.stocktradersdaily.com/news_release/101/Behavioral_Patterns_of_ORIC_and_Institutional_Flows_062826044202_1782636122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-28T04:40:57", "published_display": "28 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oric Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ORIC)", "summary": "This article provides key financial data and analyst estimates for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), including current stock price, historical performance, market capitalization, and upcoming earnings dates. It also covers analyst price forecasts, past earnings results, r", "url": "https://www.tradingview.com/symbols/NASDAQ-ORIC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T04:40:17", "published_display": "26 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25", "summary": "H.C. Wainwright has reiterated its Buy rating for Oric Pharmaceuticals (ORIC.US) and maintained a target price of $25. This action signals continued confidence in the company's prospects from the analyst firm.", "url": "https://www.moomoo.com/news/post/71964510/hc-wainwright-maintains-oric-pharmaceuticals-oricus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-25T01:39:32", "published_display": "25 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC Pharmaceuticals (ORIC) shareholders back updated equity plan and annual say-on-pay", "summary": "ORIC Pharmaceuticals' stockholders have approved an amended 2020 Equity Incentive Plan, which revises the annual share increase and clarifies limits on incentive stock options. The company also announced the election of two Class III directors, ratification of KPMG LLP as auditor", "url": "https://www.stocktitan.net/sec-filings/ORIC/8-k-oric-pharmaceuticals-inc-reports-material-event-aabc7cf87105.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:51", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOcGlZYjdtWUN4WERFYlFoYWFjb1VnQWE1QTlBLUZ4anBqaHRiMzZKdWNFVk1kWTVjZEg0dVpfaWhOdm45Nk14MTJjYWJuQkRNbTJEMVA2bDNKX2NDQzdEWDBNTXFjUHU3WTBLcVZIQVd6d0ZmZEh5TkxaLU9xYnZfcHY5M2NsX1g0UXItcWFaWGIxcFQ4V0hOd3VxUHc4U0N3ZmdubDBUYXdkQTFGYjE0Qm9ZaFN4OWZRVWZXei12X2tLWlJoOEVFVkVScjByRnNETEdwSWRyRG9BbXVxQ0I0dnRvZFF5N2RkdWVB0gHwAUFVX3lxTE1IOTBPTGlYdjI3bkx4SVRmeXRGNHpsRzFldG90M1JmS2dtLWhoRFpkR0dLYkJXM3lodkF3VFRLa0tUUjh6UnV0R1JpQzlMZHZ4em5uUE1xWHpJOTZoUmNwX1I0aHNYMEo2cEVYZGNSTnU4cXktWHUtQ085aE9teUtGSExKMHFqUGdyWnJ5X1ZuUGRBZ0Z2MlhzTERoQ3ZDYm1jNU5ZUU9yX1BjSDl1VWt2a1F1emJtNDRyaGZoNlF6bmVUUF9reldCb3lYVDJ1X25UbVVsRFREaGttVVY1UkYzZ0xhZExuM0VnaWx5NHExcA?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel initiates Oric Pharmaceuticals stock with buy rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPQmNqbTcxT0VyV1RTSUlZMjNrd25ReW9DbTJhbEg2dkgwYlhnYWpKRUNSak4wdWNLTml0SThPbEdjWUNzaktCTDJQdEgtRjlqb2JKeDVpbVFhckxjaGh2YVp5OEVMTWpLTEdpbzQ1UWRLM0RVcThLb1c4UnJ4ZjFJcE1ET282cFJyT0hnMDBYVG1SLXp2amVzTTZ5SUlOeGQ2aktIR1ZxQmhsOG1qSmo2WWthMUpMSGx5aXA4?oc=5", "source_name": "Investing.com", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQSGx5eUVpVG4yb1V6aVB4Qm9lWm9iUVlwQllnWVYzRGJrelF3WC15YmJkMk1ZakNVNjh2dzJ6bnZySjBYd0ZnM2JoV09wUXNESkNIQ0tMbVdOTnFjU2hhbzNUNllzbFoyVnVxVEJKWXJEVS1mMkZmV01iTXAxU0tLb19BTWowRzVFUUtzLTFqUTVNa0xWNG50WjRzcEIzTDFuRmZsZ2FaSDZaNUVZaFoyUWNJT2NPbEoxTVJvd1pXWGkwVEk2R0tV?oc=5", "source_name": "Streetwise Reports", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC\u00ae Pharmaceuticals to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oric-pharmaceuticals-participate-upcoming-investor-200500788.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T20:05:00+00:00", "published_display": "27 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNVnlGVWdxT1JUYzJQNkpQUUZwYlhDaEJXcVNzd0FacHpxSXZLMUhZWmsyN25Ubk5zVk9hQU1Za2F2MmY0UFBNODRYcnZBdTlUS213QWpPdGg2N3hoVWF1emllZTBUNUI0RzMxZTBwLTE0YktDRWxmSGhlWHdROGlCaE1ORWc3bi1JV01lbDFyZTdaQkZmOHI1YTlOSllTU3VxMy1peUFtcjlUVFhKbU5mRnBVWWtuYU9SeXZmLTBLOElRVnQxX25HTjRsZjhuMzNZMEJzdXpUY1A1dVNmRWRLRGZYRkNzU2otak52MzJMSFI0NVVOS0dfaGtR?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/companies-oric-pharmaceuticals-nasdaq-oric-132304648.html", "source_name": "Simply Wall St.", "published_at": "2026-05-17T13:23:04+00:00", "published_display": "17 May 2026 13:23", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ORIC\u00ae Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQM2g0dW5nT0VCWkFnWmdJTWsybF9iY3N0cTdBcVNMbVlHME0zVzZWeFFJN0tJYnJjc0p0NzFLSHkwanZlZlNTMkhUdDdoQndINkl1Qzd1MlhQQllKdWRrN0hPbDQwekxTb3Z2bkxWOHpQRE9pblZfcGoxWTExYVZya2pKQy1tb25weWQ3LVcybzZ6dEJjUkhfYWNVTXpybzZqWDVnOHJCTjFkekNNcW00TGgwRE9IWXJ5c3JCYzh1WVRXSjYxMVc1czB2WDItY2U2SERldVRhaFFWS1pZTGVZQzA3cXUwQS1rb1FLWUxUQ3ctMFU?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At ORIC Pharmaceuticals (ORIC) Valuation After New Rinzimetostat AACR Prostate Cancer Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ORIC\u00ae Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oric-pharmaceuticals-presents-preclinical-data-200500912.html", "source_name": "GlobeNewswire", "published_at": "2026-04-17T20:05:00+00:00", "published_display": "17 Apr 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQSHZwVFEwdW1QLWl5c0Q1cU9iU3JNT3VvMVlLSUw1MlQyYTFqVHNoUzhCNWREYUF4cGwxWDZBVURoMTJQQ1lyNXVnUXhHd2FmQ0ViNUEyNWNMU3RDYldYUHhFeHhoczBYZ3B1NkprSW9NTXpMaTZXSmE0cnp4M3A0Nk9LSG96WUN5UzlmbkxVeXJXN1BLTWxDMkhOZjZEZEE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ORIC\u00ae Pharmaceuticals Announces $125 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPZ3JMSTBaSlBXVHJQVjI3bEZZLWJZS1l5dTF0LWFocF9qcEwtUkk2Ui14cEduYUk2eWZrTkswcjV5SXlEdl8zUDR3UGRxQko4Y0NZRmdXWGk2YVVsVV82NlpqUG9oYXJDYkY4OGRIWEp0cXVTbUM4aEMtOU9TaTJfZUtKTV96UmxFU3JyRzdkQUNQaWU2LU9QcFE4Vzd1VHlvZF9GRXJ2SUl5WHRJWEZwRGNCcjFVWGNXRXNJYmFuODR6RWJobXF6OEs0WnRwd21zNTl1S3I2azd3dw?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-05-28T07:00:00+00:00", "published_display": "28 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oric Pharmaceuticals Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1aa2VqdVNGV3FmdVNqYU53MFdodWZma1gtRE9Ybm1XN2VPZm1qUGpvT2ljTTBPR1hxT09vSUlpcHFKbDVUUWJLa1RHWmxpdTJIQ0RB?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T03:35:07+00:00", "published_display": "25 Apr 2025 03:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "How ORIC\u2019s Global Phase 3 Rinzimetostat Trial with Bayer\u2019s NUBEQA Has Changed Its Investment Story (ORIC)", "summary": "ORIC Pharmaceuticals has launched the Himalayas-1 global Phase 3 trial for rinzimetostat with Bayer's NUBEQA in metastatic castration-resistant prostate cancer, enrolling about 600 patients. This trial positions rinzimetostat as a late-stage asset and a major clinical catalyst fo", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/how-orics-global-phase-3-rinzimetostat-trial-with-bayers-nub/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-15T11:43:51", "published_display": "15 Jul 2026 11:43", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC Pharmaceuticals initiates phase 3 prostate cancer trial", "summary": "ORIC Pharmaceuticals (NASDAQ:ORIC) has initiated its Himalayas-1 global Phase 3 trial for metastatic castration-resistant prostate cancer, enrolling approximately 600 patients across 25 countries. The trial will evaluate rinzimetostat in combination with darolutamide, with primar", "url": "https://m.uk.investing.com/news/stock-market-news/oric-pharmaceuticals-initiates-phase-3-prostate-cancer-trial-93CH-4770442?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-15T02:42:00", "published_display": "15 Jul 2026 02:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/oric-pharmaceuticals-starts-phase-3-210723202.html", "source_name": "MT Newswires", "published_at": "2026-07-14T21:07:23+00:00", "published_display": "14 Jul 2026 21:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC\u00ae Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA\u00ae (Darolutamide), Supported by Clinical Collaboration with Bayer", "summary": "ORIC Pharmaceuticals has initiated the Himalayas-1 global Phase 3 registrational trial for metastatic castration-resistant prostate cancer (mCRPC), evaluating rinzimetostat in combination with Bayer's NUBEQA\u00ae (darolutamide). This trial, supported by a collaboration with Bayer pro", "url": "https://www.manilatimes.net/2026/07/15/tmt-newswire/globenewswire/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with-bayer/2384536", "source_name": "The Manila Times", "published_at": "2026-07-14T20:26:57", "published_display": "14 Jul 2026 20:26", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bayer Will Provide NUBEQA at No Cost for ORIC\u2019s Global Trial", "summary": "ORIC Pharmaceuticals announced the initiation of its global Phase 3 Himalayas-1 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC), in collaboration with Bayer. Bayer will supply NUBEQA (darolutamide) free of charge for the trial, which will enroll", "url": "https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-awcsgl0auq0k.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:04:57", "published_display": "14 Jul 2026 20:04", "sentiment": "positive", "sentiment_pct": 70, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in ORIC Response", "summary": "Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is exhibiting mixed sentiment with a mid-channel oscillation pattern. AI models have generated three distinct trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014tailored to different risk profiles. The analysis highlights an ", "url": "https://news.stocktradersdaily.com/news_release/91/Discipline_and_Rules-Based_Execution_in_ORIC_Response_070926055001_1783590601.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-09T05:41:49", "published_display": "09 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oric Pharmaceuticals director Heyman sells $3,600 in stock", "summary": "Richard A. Heyman, a director at Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), sold 300 shares of company stock for $3,600. The transaction was executed on July 6, 2026, under a Rule 10b5-1 trading plan. This sale comes amidst significant analyst upgrades and promising clinical data ", "url": "https://www.investing.com/news/insider-trading-news/oric-pharmaceuticals-director-heyman-sells-3600-in-stock-93CH-4782496", "source_name": "Investing.com", "published_at": "2026-07-08T23:11:07", "published_display": "08 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Oric Pharmaceuticals Inc For: 8 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Oric Pharmaceuticals Inc. on July 8th. The brief piece indicates that ORIC experienced a slight increase of 0.32%. The content primarily presents market data and related news.", "url": "https://ng.investing.com/news/stock-market-news/form-4-oric-pharmaceuticalsinc-for-8-july-93CH-2591808", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T21:41:49", "published_display": "08 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oric Pharmaceuticals (ORIC) entity sells 300 shares under 10b5-1 plan", "summary": "An entity linked to Oric Pharmaceuticals director Richard A. Heyman, RAHD Capital, LLC, sold 300 shares of ORIC common stock at $12.00 per share on July 6, 2", "url": "https://www.stocktitan.net/sec-filings/ORIC/form-4-oric-pharmaceuticals-inc-insider-trading-activity-0373dc5a5db7.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:11:07", "published_display": "08 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Oric Pharmaceuticals, Inc. \u2013 NASDAQ:ORIC", "summary": "This article provides a financial overview for Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) on TradingView. It specifically highlights the company's forward price-to-sales ratio. The content also lists various features and financial data points available through the TradingView plat", "url": "https://www.tradingview.com/symbols/NASDAQ-ORIC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T19:09:28", "published_display": "07 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC focuses on oncology pipeline as Oric Pharmaceuticals positions for long-term growth", "summary": "Oric Pharmaceuticals (ORIC) is a clinical-stage biotechnology company concentrating on small-molecule therapies to overcome resistance mechanisms in cancer treatment, a significant challenge in oncology. The company's strategy involves translating preclinical insights into clinic", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/oric-focuses-on-oncology-pipeline-as-oric-pharmaceuticals-positions-for/69715694", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:40:48", "published_display": "07 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Oric Pharmaceuticals, Inc. \u2013 DUS:4TZ", "summary": "This article provides financial information for Oric Pharmaceuticals, Inc. (DUS:4TZ), specifically focusing on its forward price-to-sales ratio. The content is sourced from TradingView and includes data from ICE Data Services and FactSet, indicating a focus on financial metrics f", "url": "https://www.tradingview.com/symbols/DUS-4TZ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T10:40:48", "published_display": "07 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan", "summary": "Oric Pharmaceuticals (NASDAQ: ORIC) filed a Form 144 indicating a proposed sale of 7,000 Common shares through J.P. Morgan Securities LLC. The filing details two stock option exercises, each for 3,500 shares, dated August 25, 2016, and July 6, 2026. This notification provides tra", "url": "https://www.stocktitan.net/sec-filings/ORIC/144-oric-pharmaceuticals-inc-sec-filing-0e54b280e9c2.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:12:06", "published_display": "06 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Oric Pharmaceuticals, Inc. SEC Filing", "summary": "Oric Pharmaceuticals, Inc. (ORIC) filed a Form 144 with the SEC, indicating a proposed sale of 6,400 common shares by a filer who acquired them via stock option exercise on July 31, 2015. The shares, valued at $76,800, are expected to be sold on July 6, 2026, through J.P. Morgan ", "url": "https://www.stocktitan.net/sec-filings/ORIC/144-oric-pharmaceuticals-inc-sec-filing-0ed3d636d605.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:12:06", "published_display": "06 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Oric Pharmaceuticals, Inc. \u2013 NASDAQ:ORIC", "summary": "This page from TradingView provides financial information specifically focusing on the \"Price to earnings forward\" metric for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC). It indicates the company's ticker symbol, NASDAQ listing, and highlights specific financial data points related ", "url": "https://www.tradingview.com/symbols/NASDAQ-ORIC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:11:00", "published_display": "04 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "ORIC Pharmaceuticals announced inducement grants to three new non-executive employees, consisting of 44,400 non-qualified stock options and 7,200 restricted stock units. These grants were approved by ORIC's Compensation Committee and serve as a material inducement to employment i", "url": "https://www.globenewswire.com/news-release/2026/07/02/3321570/0/en/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-03T05:39:58", "published_display": "03 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC awards new hires 44,400 stock options and 7,200 RSUs", "summary": "ORIC Pharmaceuticals (Nasdaq: ORIC) announced inducement equity grants to three new non-executive employees who started in June 2026. The grants, made on July 1, 2026, include 44,400 non-qualified stock options and 7,200 restricted stock units, approved under Nasdaq Rule 5635(c)(", "url": "https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-64rrrbs3lx9a.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:29", "published_display": "02 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Are Bullish on Top Healthcare Picks", "summary": "Wall Street analysts are showing bullish sentiment towards several healthcare companies, including Monopar Therapeutics Inc (MNPR), Oric Pharmaceuticals (ORIC), and Tango Therapeutics (TNGX). Analysts from Piper Sandler, Barclays, H.C. Wainwright, and Canaccord Genuity have issue", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3050918/wall-street-analysts-are-bullish-on-top-healthcare-picks/", "source_name": "The Globe and Mail", "published_at": "2026-07-01T04:40:30", "published_display": "01 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation", "summary": "Wedbush has reiterated its \"outperform\" recommendation for ORIC Pharmaceuticals (ORIC). The article is brief and does not provide further details on the rationale behind this rating.", "url": "https://www.msn.com/en-us/money/markets/wedbush-reiterates-oric-pharmaceuticals-oric-outperform-recommendation/ar-AA1RYzxw?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-30T04:40:30", "published_display": "30 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. \u2013 NASDAQ:ORIC", "summary": "The article provides a financial overview of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), focusing on its enterprise value to EBITDA forward metric. It details the company's financial data on the TradingView platform, including market performance and other financial indicators. The", "url": "https://www.tradingview.com/symbols/NASDAQ-ORIC/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T08:14:17", "published_display": "29 Jun 2026 08:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Oric Pharmaceuticals, Inc. \u2013 FWB:4TZ", "summary": "This article provides the \"Price to book forward\" value for Oric Pharmaceuticals, Inc. (FWB:4TZ) on the Frankfurt Stock Exchange. It indicates that the market is currently closed with no trades. The article also lists various financial and community features available on the Trad", "url": "https://www.tradingview.com/symbols/FWB-4TZ/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:09:46", "published_display": "29 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Oric Pharmaceuticals, Inc. \u2013 NASDAQ:ORIC", "summary": "This article focuses on the enterprise value to EBIT forward for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC). It appears to be a financial data point presented on TradingView, indicating a specific financial metric for the company. The content primarily consists of navigation and bo", "url": "https://www.tradingview.com/symbols/NASDAQ-ORIC/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:09:46", "published_display": "28 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of ORIC and Institutional Flows", "summary": "This article analyzes Oric Pharmaceuticals Inc. (NASDAQ: ORIC), identifying strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with specific entry, target, and stop-loss l", "url": "https://news.stocktradersdaily.com/news_release/101/Behavioral_Patterns_of_ORIC_and_Institutional_Flows_062826044202_1782636122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-28T04:40:57", "published_display": "28 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oric Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ORIC)", "summary": "This article provides key financial data and analyst estimates for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), including current stock price, historical performance, market capitalization, and upcoming earnings dates. It also covers analyst price forecasts, past earnings results, r", "url": "https://www.tradingview.com/symbols/NASDAQ-ORIC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T04:40:17", "published_display": "26 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25", "summary": "H.C. Wainwright has reiterated its Buy rating for Oric Pharmaceuticals (ORIC.US) and maintained a target price of $25. This action signals continued confidence in the company's prospects from the analyst firm.", "url": "https://www.moomoo.com/news/post/71964510/hc-wainwright-maintains-oric-pharmaceuticals-oricus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-25T01:39:32", "published_display": "25 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC Pharmaceuticals (ORIC) shareholders back updated equity plan and annual say-on-pay", "summary": "ORIC Pharmaceuticals' stockholders have approved an amended 2020 Equity Incentive Plan, which revises the annual share increase and clarifies limits on incentive stock options. The company also announced the election of two Class III directors, ratification of KPMG LLP as auditor", "url": "https://www.stocktitan.net/sec-filings/ORIC/8-k-oric-pharmaceuticals-inc-reports-material-event-aabc7cf87105.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:51", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel initiates Oric Pharmaceuticals stock with buy rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPQmNqbTcxT0VyV1RTSUlZMjNrd25ReW9DbTJhbEg2dkgwYlhnYWpKRUNSak4wdWNLTml0SThPbEdjWUNzaktCTDJQdEgtRjlqb2JKeDVpbVFhckxjaGh2YVp5OEVMTWpLTEdpbzQ1UWRLM0RVcThLb1c4UnJ4ZjFJcE1ET282cFJyT0hnMDBYVG1SLXp2amVzTTZ5SUlOeGQ2aktIR1ZxQmhsOG1qSmo2WWthMUpMSGx5aXA4?oc=5", "source_name": "Investing.com", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQSGx5eUVpVG4yb1V6aVB4Qm9lWm9iUVlwQllnWVYzRGJrelF3WC15YmJkMk1ZakNVNjh2dzJ6bnZySjBYd0ZnM2JoV09wUXNESkNIQ0tMbVdOTnFjU2hhbzNUNllzbFoyVnVxVEJKWXJEVS1mMkZmV01iTXAxU0tLb19BTWowRzVFUUtzLTFqUTVNa0xWNG50WjRzcEIzTDFuRmZsZ2FaSDZaNUVZaFoyUWNJT2NPbEoxTVJvd1pXWGkwVEk2R0tV?oc=5", "source_name": "Streetwise Reports", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC\u00ae Pharmaceuticals to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oric-pharmaceuticals-participate-upcoming-investor-200500788.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T20:05:00+00:00", "published_display": "27 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNVnlGVWdxT1JUYzJQNkpQUUZwYlhDaEJXcVNzd0FacHpxSXZLMUhZWmsyN25Ubk5zVk9hQU1Za2F2MmY0UFBNODRYcnZBdTlUS213QWpPdGg2N3hoVWF1emllZTBUNUI0RzMxZTBwLTE0YktDRWxmSGhlWHdROGlCaE1ORWc3bi1JV01lbDFyZTdaQkZmOHI1YTlOSllTU3VxMy1peUFtcjlUVFhKbU5mRnBVWWtuYU9SeXZmLTBLOElRVnQxX25HTjRsZjhuMzNZMEJzdXpUY1A1dVNmRWRLRGZYRkNzU2otak52MzJMSFI0NVVOS0dfaGtR?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/companies-oric-pharmaceuticals-nasdaq-oric-132304648.html", "source_name": "Simply Wall St.", "published_at": "2026-05-17T13:23:04+00:00", "published_display": "17 May 2026 13:23", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC\u00ae Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQM2g0dW5nT0VCWkFnWmdJTWsybF9iY3N0cTdBcVNMbVlHME0zVzZWeFFJN0tJYnJjc0p0NzFLSHkwanZlZlNTMkhUdDdoQndINkl1Qzd1MlhQQllKdWRrN0hPbDQwekxTb3Z2bkxWOHpQRE9pblZfcGoxWTExYVZya2pKQy1tb25weWQ3LVcybzZ6dEJjUkhfYWNVTXpybzZqWDVnOHJCTjFkekNNcW00TGgwRE9IWXJ5c3JCYzh1WVRXSjYxMVc1czB2WDItY2U2SERldVRhaFFWS1pZTGVZQzA3cXUwQS1rb1FLWUxUQ3ctMFU?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At ORIC Pharmaceuticals (ORIC) Valuation After New Rinzimetostat AACR Prostate Cancer Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC\u00ae Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/oric-pharmaceuticals-presents-preclinical-data-200500912.html", "source_name": "GlobeNewswire", "published_at": "2026-04-17T20:05:00+00:00", "published_display": "17 Apr 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQSHZwVFEwdW1QLWl5c0Q1cU9iU3JNT3VvMVlLSUw1MlQyYTFqVHNoUzhCNWREYUF4cGwxWDZBVURoMTJQQ1lyNXVnUXhHd2FmQ0ViNUEyNWNMU3RDYldYUHhFeHhoczBYZ3B1NkprSW9NTXpMaTZXSmE0cnp4M3A0Nk9LSG96WUN5UzlmbkxVeXJXN1BLTWxDMkhOZjZEZEE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ORIC\u00ae Pharmaceuticals Announces $125 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPZ3JMSTBaSlBXVHJQVjI3bEZZLWJZS1l5dTF0LWFocF9qcEwtUkk2Ui14cEduYUk2eWZrTkswcjV5SXlEdl8zUDR3UGRxQko4Y0NZRmdXWGk2YVVsVV82NlpqUG9oYXJDYkY4OGRIWEp0cXVTbUM4aEMtOU9TaTJfZUtKTV96UmxFU3JyRzdkQUNQaWU2LU9QcFE4Vzd1VHlvZF9GRXJ2SUl5WHRJWEZwRGNCcjFVWGNXRXNJYmFuODR6RWJobXF6OEs0WnRwd21zNTl1S3I2azd3dw?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-05-28T07:00:00+00:00", "published_display": "28 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oric Pharmaceuticals Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1aa2VqdVNGV3FmdVNqYU53MFdodWZma1gtRE9Ybm1XN2VPZm1qUGpvT2ljTTBPR1hxT09vSUlpcHFKbDVUUWJLa1RHWmxpdTJIQ0RB?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T03:35:07+00:00", "published_display": "25 Apr 2025 03:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 46, "sentiment_summary": {"positive": 14, "negative": 2, "neutral": 30, "score": 56, "total": 46, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 15.4, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 10.85, "latest_week": "2026-07-10", "one_week_move": -6.8, "four_week_move": 31.2, "twelve_week_move": 0.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.041534, "market_dynamics_buy_signal": false, "relative_strength": -12.581314, "fair_value_gap": 14.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 52.7477, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.8% over one week, +31.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 7}, {"label": "Market source", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Simply Wall Street", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 38}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 4}, {"label": "Macro sensitivity", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "38", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.8% over one week, +31.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "How ORIC\u2019s Global Phase 3 Rinzimetostat Trial with Bayer\u2019s NUBEQA Has Changed Its Investment Story (ORIC)"}], "updated_at": "2026-07-16T00:50:01.763163+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}